BIRMINGHAM law firm Wragge & Co's life sciences team has advised Netherlands and Belgium-based biopharmaceutical company arGEN-X on a cross-border licensing agreement with Shanghai-headquartered RuiYi.

Under the agreement, RuiYi gains the right to develop and commercialise an antibody, ARGX-109, for the treatment of a range of inflammatory and oncology diseases.

RuiYi will make up front payments in cash and equity to arGEN-X, as well as further payments in royalties and on achievement of agreed clinical, regulat......for the full story register now for free or login below...